Hester Biosciences Q2 Net up 48 percent at Rs 8.85 crore
New Delhi: Animal healthcare firm Hester Biosciences reported a 47.99 percent rise in its standalone net profit to Rs 8.85 crore for the September quarter, mainly on account of robust sales in large divisions.
The company had posted a net profit of Rs 5.98 crore for the corresponding period of the previous fiscal, Hester Biosciences said in a BSE filing.
"The operations indicate that the large animal vaccine business has a good potential for improving the profitability of the company. The growth anticipated is also from the large animal vaccines," the company said.
Standalone net sales of the company also rose to Rs 38.47 crore for the quarter under consideration as against Rs 30.17 crore in the same period year ago.
In a separate filing, Hester Biosciences Ltd said its board has declared an interim dividend of Rs 4 per equity share on the face value of Rs 10 per share, for the financial year 2017-18.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd